China In-Licensing Crossroads: Zai Lab, Everest March Towards Market But BioNova Returns Rights

 
• By Dexter Jie Yan
  
in-licensing at a crossroads
Amid funding crunch, Chinese in-licensing players reach crossroads toward commercialization • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia